SenoRx, Inc. (NASDAQ:SENO)

CAPS Rating: No stars

The Company develops, manufactures and sells minimally-invasive medical devices for the diagnosis of breast cancer.

Results 1 - 3 of 3

Recs

0
Member Avatar MstrGold (30.59) Submitted: 6/9/2010 6:49:39 AM : Underperform Start Price: $7.03 SENO Score: +20.40

Company is overvalued in terms of fundamental prospects (source Ultralong).

Recs

0
Member Avatar jhe2jhe (38.67) Submitted: 9/27/2007 7:01:37 PM : Outperform Start Price: $8.38 SENO Score: -10.30

Great startup will do well. Very good business lan in a much needed area with outstanding products

Recs

0
Member Avatar JhansiKiRani (69.75) Submitted: 6/27/2007 11:44:42 AM : Outperform Start Price: $9.83 SENO Score: -34.05

It's already outeperformed S & P once.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement